Abstract: Disclosed herein are salt and solvate forms of (4S,7aR,9aR,10R,11E,14S,15R)-6?-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3?,4?,7a,8,9,9a,10,13,14,15-decahydro-2?H,3H,5H-spiro[1,19-etheno-16,16-cyclobuta[i][1,4]oxazepino[3,4-f][1,2,7]thiadlazacyclohexadecine-4,1 naphthalene]-16,16,18 (7H,17H)-trione (AMG 397): (AMG 397), such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.

Abstract: Disclosed herein are crystalline forms of (4S,7aR,9aR,10R,11E,14S,15R)-6?-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3?,4?,7a,8,9,9a,10,13,14,15-decahydro-2?H,3H,5H-spiro[1,19-etheno-1616-cyclobuta[i] [1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-4,1?-naphthalene]-16,16,18(7H,17H)-trione (AMG 397): (AMG 397), hydrates, and solvates thereof. Also disclosed are methods of making the crystalline forms, and methods of treating diseases and disorders with the crystalline forms.

Abstract: Disclosed herein are crystalline and amorphous forms of (1S,3?R,6?R,7?S,8?E,11?S,12?R)-6-chloro-7?-methoxy-11?,12?-dimethyl-3,4-dihydro-2H, 15?H-spiro[naphthalene-1,22?-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6,019,24]pentacosa[8,16,18,24]tetraen]-15?-one 13?,13?-dioxide (AMG 176): and salts and hydrates thereof. Also disclosed are methods of making the crystalline and amorphous forms, and methods of treating diseases and disorders with the crystalline and amorphous forms.

Abstract: Electronic submissions, such as those for capital markets, are processed by evaluating the data contained in the electronic submissions against failure conditions. The failure conditions may include a static failure condition and a scalar failure condition. The static failure condition identifies a data element that is to be present or absent for the static failure condition to be met. The scalar failure condition identifies data that is to conform to an inequation for the scalar failure condition to be met. The electronic submission can be approved upon completion of the evaluation when all failure conditions are not met. The electronic submission can be thus approved with no human analyst intervention or review needed. When one or more failure condition is met, the electronic submission requires further analysis. Specific advantageous failure conditions are discussed. Feedback can be employed to increase approvals that trigger no failure conditions.

Abstract: A method of treating a disease associated with activated B lymphocytes expressing Tetraspanin 33 (TSPAN33/BAAM). The disease can be, for example, lymphoma or an immune disease. The method includes administering an anti-TSPAN33/BAAM antibody to a patient in need of such treatment in an amount effective to treat the disease. Methods of purifying activated B cells and identifying activated and/or diseased B cells are also provided.

Abstract: The present invention relates to crystalline polymorph forms of (1S)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.